Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Novavax COVID-19 vaccine more than 90% effective in U.S. trial

Stock MarketsJun 14, 2021 12:05PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Vials labelled "COVID-19 Coronavirus Vaccine" and syringe are seen in front of displayed Novavax logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

By Carl O'Donnell

(Reuters) -Novavax Inc on Monday said its COVID-19 vaccine was more than 90% effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.

The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax (NASDAQ:NVAX) on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.

The protein-based vaccine was more than 93% effective against the more easily transmissible predominant coronavirus variants that have caused concern among scientists and public health officials, Novavax said.

Protein-based vaccines are a conventional approach that use purified pieces of the virus to spur an immune response, such as those used against whooping cough and shingles.

While the trial was being conducted, the virus variant first discovered in the United Kingdom and now known as the Alpha variant was the most common circulating in the United States, the company said.

The concerning variants first identified in Brazil, South Africa and India were also detected among the trial's participants, Novavax's head of research and development, Dr. Gregory Glenn, told Reuters.

The vaccine was 91% effective among volunteers at high risk of severe infection and 100% effective in preventing moderate and severe cases of COVID-19. It was roughly 70% effective against virus variants that Novavax was unable to identify, Glenn said.

"Practically speaking, it's very important that the vaccine can protect against a virus that is wildly swinging around" in terms of new variants, Glenn said.

Novavax said the vaccine was generally well tolerated. Side effects included headache, fatigue and muscle pain and were generally mild. A small number of participants experienced side effects described as severe.

Novavax remains on track to produce 100 million doses per month by the end of the third quarter of 2021 and 150 million doses per month in the fourth quarter of 2021, the company said.

Chief Executive Stanley Erck told CNBC on Monday it is possible the United States could donate the 110 million shots Novavax has agreed to supply to the U.S. government to the COVAX program that provides COVID-19 vaccines to poorer countries.

The Maryland-based company has repeatedly pushed back production forecasts and has struggled to access raw materials and equipment needed to manufacture its vaccine.

However, in a May investor call, Erck said major manufacturing hurdles have been cleared and that all of its facilities can now produce COVID-19 vaccine at commercial scale.

Erck said Novavax has begun its regulatory filing in India in partnership with the Serum Institute of India (SII), which is contracted to make Novavax shots.

Erck said his understanding is that SII is no longer constrained by raw materials shortages.

SII had said in March that U.S. restrictions on exports of supplies used for vaccines were limiting its ability to scale up production.

Novavax shares were off 3% in midday trading.

Novavax COVID-19 vaccine more than 90% effective in U.S. trial
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email